← Human Trials & Peer-Reviewed Studies
Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial
Plain-language guide to PMID 17291938 (2007): double-blind randomized controlled trial study of BNP (Nesiritide).
Key Facts
- PMID
- 17291938
- Journal
- Journal of the American College of Cardiology
- Year
- 2007
- Study type
- Randomized Controlled Trial
- Authors
- Mentzer RM Jr et al. (7 authors)
- DOI
- 10.1016/j.jacc.2006.10.048
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at BNP (Nesiritide).
The purpose of this study was to determine the role nesiritide might play in patients with left ventricular dysfunction undergoing coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB).
Why It Was Studied
Given the hemodynamic, neurohormonal, and renal effects of natriuretic peptides, nesiritide might be useful in the management of patients undergoing cardiac surgery.
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
Postoperative renal function, hemodynamics, and drug use (primary end points) were assessed in patients who underwent CABG using CPB; mortality and safety (secondary end points) were assessed in all patients who received the study drug.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.
As a double-blind BNP (Nesiritide) study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with BNP (Nesiritide) could be set against what happens without it.
What Was Measured
PubMed files the paper under topics including Cardiac Surgical Procedures, Cardiopulmonary Bypass, Coronary Artery Bypass, Heart Diseases, Natriuretic Agents, Natriuretic Peptide, Brain and Perioperative Care.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide).
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2007 (Journal of the American College of Cardiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.